Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 20/20 | 0.69 |
| ▸ | GNA15 | P30679 | 1/20 | 0.55 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.55 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.55 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.55 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15800616 | 0.92 | FFAR1 (0.60) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16448773 | 0.89 | FFAR1 (0.67) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16448783 | 0.88 | FFAR1 (0.66) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL1688252 | 0.88 | FFAR1 (0.66) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL204587 | 0.87 | FFAR1 (0.56) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL204792 | 0.87 | FFAR1 (0.59) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16448792 | 0.86 | FFAR1 (0.69) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL27962432 | 0.86 | FFAR1 (0.63) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL15229740 | 0.86 | FFAR1 (0.63) | FFAR1 | |
| SCHEMBL16523399 | 0.85 | FFAR1 (0.65) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2880028-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| US-9527875-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527875-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | KANG, XINSHAN (CN) | 2016-07-14 | — | — | US | disclosed |
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | KANG, XINSHAN (CN) | 2016-07-14 | — | — | US | disclosed |
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2015-07-09 | — | — | US | disclosed |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2015-07-09 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| WO-2008001931-A2 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | GPR119, GLP1R, INSR | FFAR1 9/4885GNA15 1628/4885SLC10A1 140/4885 |
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | FFAR1 27/4885GNA15 494/4885SLC10A1 367/4885 |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | FFAR1 15/4885GNA15 584/4885SLC10A1 86/4885 |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | FFAR1 25/4885GNA15 505/4885SLC10A1 202/4885 |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | FFAR1 19/4885GNA15 948/4885SLC10A1 129/4885 |
| US-20100197761-A1 | Fused cyclic compounds | GPR119, GLP1R, GPR65 | FFAR1 15/4885GNA15 584/4885SLC10A1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.